You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Illumina said it raised Q4 and full-year top- and bottom-line expectations, remained on a trajectory toward high single-digit growth in 2027 and 500 basis points of margin expansion ex-M&A, but declined to commit to 2027 guidance.
Illumina reported Q3 2026 revenue of $1,129 million and net income of $220 million, versus $1,084 million and $150 million in Q3 2025. Nine-month operating cash flow was $909 million; its SomaLogic acquisition had a purchase price of $460 million.
Illumina reported Q3 2026 revenue of $1.13 billion, up 4.2%, and raised fiscal year 2026 revenue guidance to $4.64-$4.66 billion and non-GAAP diluted EPS guidance to $5.40-$5.45. Non-GAAP diluted EPS excluding tariff refunds was $1.44.
Illumina, Inc. established an unsecured commercial paper program on October 8, 2026, capped at $1.0 billion, with maturities not exceeding 397 days. Proceeds are expected to be used for general corporate purposes; no notes were outstanding, and three dealers initially participated.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Illumina reported Q4 2025 results above expectations, with 20% ex-China clinical consumables growth and full-year ex-China revenue up 2%, and guided 2026 total revenue of $4.5–$4.6 billion (4–6% reported growth) with operating margin expansion of ~130 bps ex-Somalogic, while research and applied consumables are expected to decline mid- to high single-digits and China remains a headwind due to export restrictions.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Capital expenditures for free cash flow purposes | $41M | Q3 2026 | — |
|
|
|||
| Cash flow provided by operations | $419M | Q3 2026 | — |
| Free cash flow non-GAAP | $791M | Nine Months Ended September 27, 2026 | — |
|
|
|||
| Non-GAAP gross margin (b) non-GAAP | 75.3% | Three Months Ended September 27, 2026 | — |
| Non-GAAP operating margin non-GAAP | 28.8% | Three Months Ended September 27, 2026 | — |
| Non-GAAP operating margin, excluding tariff refunds non-GAAP | 25% | Three Months Ended September 27, 2026 | — |
| Non-GAAP operating profit (b) non-GAAP | $824M | Nine Months Ended September 27, 2026 | — |
| Non-GAAP operating profit, excluding tariff refunds (b) non-GAAP | $791M | Nine Months Ended September 27, 2026 | — |
| Organic revenue growth (non-GAAP) (a) non-GAAP | 4.2% | Nine Months Ended September 27, 2026 | — |
|
|
|||
| Revenue growth, excluding tariff refunds (non-GAAP) (a) non-GAAP | 7.3% | Nine Months Ended September 27, 2026 | — |
| ROW organic revenue growth (non-GAAP) (a) non-GAAP | 4.7% | Three Months Ended September 27, 2026 | — |
|
|
|||
| Number of shares repurchased | 942K | Q2 2026 filing | — |
| Total cost of shares repurchased | $123M | Q2 2026 filing | — |
| Depreciation and amortization expense | $70M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ILMN
this stock
Illumina, Inc.
|
$31.30B | +57.8% | -0.7% | 35.6 | 5.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$259.44B | +20.8% | +14.5% | 36.9 | 1.3% |
|
DHR
Danaher Corp
|
$163.94B | +1.8% | +8.5% | 38.1 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.48B | +4.1% | +10.4% | 47.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.04B | +27.8% | +6.4% | 34.2 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Illumina said it raised Q4 and full-year top- and bottom-line expectations, remained on a trajectory toward high single-digit growth in 2027 and 500 basis points of margin expansion ex-M&A, but declined to commit to 2027 guidance.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ILMN | -2.9% | -21.2% | +42.5% | -12.3% | +57.8% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -5.5% | -20.0% | +42.0% | -12.1% | +47.2% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
